A role of JAK in the pathogenesis of Philadelphia negative myeloproliferative neoplasms. Target therapy possibilities
Journal Title: OncoReview - Year 2011, Vol 1, Issue 3
Abstract
In recent years a significant progress has been made in understanding of the pathogenesis of myeloproliferative neoplasms, especially the one with mutation in JAK2 gene. In 2005 several study groups confirmed the presence of V617F mutation in exon 14 of JAK2 gene. It was documented that anomaly is present in 96% of polycythaemia vera patients (PV), in 35–70% of patients with essential thrombocythaemia (ET ) and in about 50% of patients with idiopathic myelofibrosis (IMF). Later on, also other sequence aberrations of JAK2 gene were found in exon 12–15, among others a single nucleotide substitutions, insertions or deletions, and also insertion-deletions defects. In the case of most of the mentioned mutations, experimental studies confirmed their relations with abnormal autoinhibition process of JAK 2 and cytokine-independent proliferation of cells carrying defect. Discovery of relation between the presence of mutations in JAK2 gene gave insight to initiation of works to prepare small molecules with inhibitory activity against JAK 2. Initially, non-ATP competitive JAK 2 inhibitors for the APT -binding catalytic site were tested. Thereafter, ATP -competitive pyridones and pyrimidine analogs were independently evaluated. Most of JAK 2 inhibitors belong to ATP competitive inhibitors [TG101348 (Targe- Gen), INCB018424 (ruxolitinib, Incyte), CYT 387 (Cytopia), CEP -701 (lestaurtinib, Cephalon), XL019 (Exelixis), SB1518 (S*Bio, according to Onyx licence as ONX0803) and AZD1480 (AstraZeneca)]. Its administration in myelofibrosis leads to reduction of spleen volume in about 50% of patients, reduction of general symptoms intensity, increase of physical exercise tolerability and improvement of quality-of-life. In PV and ET patients JAK 2 inhibitors therapy resulted in significant improvement of complete blood count results and in significant reduction of flebotomy needs. Presently, most of JAK 2 inhibitors are evaluated in clinical trials. However, it seems that their use may change current standards of therapy of JAK2 positive myeloproliferative neoplasms in the nearest future.
Authors and Affiliations
Krzysztof Lewandowski
Keywords
Related Articles
- EP ID EP53110
- DOI -
- Views 218
- Downloads 0
Cukrzyca posterydowa w onkologii – zasady diagnostyki i leczenia
Jedną z grup, w której należy spodziewać się wystąpienia cukrzycy w wyniku podawania glikokortykosteroidów, są chorzy na choroby nowotworowe. Zasady rozpoznania tej formy cukrzycy nie różnią się od zasad rozpoznania inny...
Administration of liposomal doxorubicin in patients with metastatic breast cancer and significant concomitant cardiovascular conditions
A frequent dilemma faced by an oncologist about to take decision on a chemotherapeutic regime for patients with metastatic breast cancer is how to maintain balance between the expected treatment efficacy and predictable...
Percutaneous retrieval of a fractured portacath fragment in two patients undergoing long-term chemotherapy
The paper discusses two clinical cases of cancer patients undergoing chemotherapy, in whom fractured and displaced tips of portacath catheters were revealed based on plain chest imaging. In the first case, the portacath...
Physical activity and cancer
Physical activity has been shown to decrease the incidence of breast and colon cancers and most likely of cancers of the prostate, endometrium and lung. The mechanism of this effect is very complex and not completely und...
Acute coronary syndrome in patients with concomitant neoplastic disease and chemotherapy. Is clinical distinctness possible?
We present 2 cases of acute coronary syndrome in patients with concomitant neoplastic disease during chemotherapy. In both patients, we found unusual angiographic image which showed that despite the presence of very larg...